세계의 올리고뉴클레오티드 합성 시장 예측(-2030년) : 제품별, 용도별, 최종사용자별, 지역별

The oligonucleotide synthesis market is projected to reach USD 24.7 billion by 2030 from USD 10.5 billion in 2025, at a CAGR of 18.6% during the forecast period. The growth of this market is driven by several factors, such as the increasing demand for synthesized oligonucleotides like primers & probes for several research & diagnostic applications. Rising technological advancements in oligonucleotide synthesis are also expected to contribute to market growth during the forecast period.

By product, the oligonucleotide-based drugs segment accounted for the largest share of the market in 2024.

By products, the market is segmented into oligonucleotide-based drugs, synthesized oligonucleotides, reagents & consumables, and equipment. In 2024, the oligonucleotide-based drugs segment accounted for the largest share of the market. The large share of this segment can be attributed to the growing acceptance of these treatments and their proven success, especially for rare & hereditary diseases. Medications such as antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) target disease-causing genes, providing precise and personalized treatments. This growing demand is fueled by advancements in RNA-targeted therapies and delivery systems, the rising prevalence of genetic diseases, and significant investments in research and development of RNA-based treatments.

In 2024, by application, the therapeutic applications segment accounted for the largest share of the market.

The oligonucleotide synthesis market is segmented into therapeutic applications, research applications, and diagnostic applications. In 2024, the therapeutic applications segment accounted for the largest share of the market. The growth of this market is fueled by the use of oligos such as antisense and siRNA for the treatment of neurological & rare diseases, with ongoing research aiming to expand applications into the treatment of CVD and cancer. Advancements in synthesis technology are expected to fuel the demand for efficient & cost-effective therapeutic approaches, with a comprehensive understanding of molecular disease mechanisms ensuring the discovery of innovative therapeutic targets, thereby contributing to market growth in this segment.

In 2024, North America accounted for the largest share of the oligonucleotide synthesis market.

In 2024, North America accounted for the largest market share, a dominance fueled by the strong presence of key industry players and a significant surge in research initiatives dedicated to advancing oligonucleotide-based therapeutics. Additionally, North America's well-established healthcare infrastructure and favorable reimbursement policies facilitate the widespread adoption of these innovative treatments, consequently driving research applications in the region. The concentration of numerous global entities also significantly contributes to this market leadership.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Tier 1-25%, Tier 2-35%, and Tier 3- 40%
• By Designation: C-level Executives - 30%, Directors- 45%, and Others- 25%
• By Region: North America -35%, Europe - 25%, the Asia Pacific -15%, Latin America -10%, the Middle East- 10%, and Africa- 5%

Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Eurofins Scientific (Luxembourg), LGC Limited (UK), Agilent Technologies, Inc. (US), Kaneka Corporation (Japan), Maravai LifeSciences (US), Azenta US Inc. (US), Twist Bioscience (US), and GenScript (US) are some of the key companies profiled in the report offering products for research & diagnostic applications.

Biogen (US). Alnylam Pharmaceuticals, Inc. (US), Sarepta Therapeutics, Inc. (US), AstraZeneca (UK), Astellas Pharma Inc. (Japan), Jazz Pharmaceuticals Plc (Ireland), Nippon Shinyaku, Co. Ltd. (Japan), Ionis Pharmaceuticals, Inc. (US), and Novartis AG (Switzerland) are some of the key companies profiled in the report offering products for therapeutic applications.

Research Coverage:

This research report categorizes oligonucleotide synthesis market by Product (Oligonucleotide-based drugs, synthesized oligonucleotide, reagents & consumables, and equipment), application (therapeutic applications, research applications, and diagnostic applications), end user (hospitals, pharmaceutical & biotechnology companies, diagnostic laboratories, CROs & CMOs, and academic & research institutes), and region (North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa).

The report's scope covers detailed information regarding the primary factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the oligonucleotide synthesis market. A thorough analysis of the key industry players has been conducted to provide insights into their business overview, solutions, and services; key strategies; new product & service launches, acquisitions, and recent developments associated with the oligonucleotide synthesis market. This report covers the competitive analysis of upcoming startups in the oligonucleotide synthesis market ecosystem.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the oligonucleotide synthesis market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide information on the key market drivers, restraints, challenges, trends, and opportunities.

The report provides insights on the following :

• Analysis of key drivers (Increasing use of synthesized oligos in therapeutic and diagnostic applications, technological advancements in oligonucleotide synthesis, growing government investments in life science research & synthetic biology, and growing focus on personalized medicine), restraints (Complexities associated with oligonucleotide-based drugs), opportunities (Increasing pharma R&D investments in emerging economies), and challenges (Lack of standard regulations, challenges in targeted delivery of oligonucleotides) are influencing the growth of the oligonucleotide synthesis market.
• Product Approvals: Detailed insights on newly approved products of the oligonucleotide synthesis market.
• Market Development: Comprehensive information about lucrative markets - the report analyses the oligonucleotide synthesis market across varied regions.
• Market Diversification: Exhaustive information about new products, recent developments, and investments in the oligonucleotide synthesis market.
• Pipeline Analysis: Comprehensive information about products under clinical trials.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players, including Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), and Merck KGaA (Germany), among others offering products for research & diagnostic applications. Other companies include Biogen (US), Alnylam Pharmaceuticals, Inc. (US), and Sarepta Therapeutics, Inc. (US), among others, for the therapeutic applications segment.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 INCLUSIONS & EXCLUSIONS
• 1.4 MARKET SCOPE
  • 1.4.1 YEARS CONSIDERED
  • 1.4.2 CURRENCY CONSIDERED
• 1.5 RESEARCH LIMITATIONS
• 1.6 STAKEHOLDERS
• 1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
  • 2.1.2 PRIMARY DATA
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 MARKET SIZE ASSESSMENT, SEGMENT LEVEL
• 2.3 MARKET GROWTH FORECAST
• 2.4 OLIGONUCLEOTIDE-BASED DRUGS MARKET VOLUME ESTIMATION
• 2.5 MARKET BREAKDOWN & DATA TRIANGULATION
• 2.6 STUDY ASSUMPTIONS
• 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 OLIGONUCLEOTIDE SYNTHESIS MARKET OVERVIEW
• 4.2 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION & COUNTRY (2024)
• 4.3 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2025 VS. 2030
• 4.4 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2024
• 4.5 OLIGONUCLEOTIDE SYNTHESIS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Increasing use of synthesized oligos in therapeutic & diagnostic applications
    • 5.2.1.2 Technological advancements
    • 5.2.1.3 Growing government investments in life science research & synthetic biology
    • 5.2.1.4 Growing focus on precision/personalized medicine
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Complexities associated with therapeutic oligonucleotides
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Increasing R&D investments by key players in emerging economies
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Lack of standard regulations
    • 5.2.4.2 Delivery of oligonucleotide drugs to specific targets
• 5.3 INDUSTRY TRENDS
  • 5.3.1 GROWING FOCUS ON DEVELOPMENT OF DRUG DELIVERY TECHNOLOGIES FOR OLIGONUCLEOTIDE-BASED DRUGS
  • 5.3.2 GROWING FOCUS ON TECHNOLOGY DEVELOPMENT FOR SUSTAINABLE & LARGE-SCALE SYNTHESIS OF OLIGONUCLEOTIDES
  • 5.3.3 FOCUS ON ACQUISITIONS TO ENHANCE MARKET POSITION
  • 5.3.4 GROWING USE OF ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS FOR TREATMENT OF NEUROLOGICAL & RARE DISEASES
• 5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.5 VALUE CHAIN ANALYSIS
• 5.6 ECOSYSTEM ANALYSIS
  • 5.6.1 ROLE IN ECOSYSTEM
• 5.7 TECHNOLOGY ANALYSIS
  • 5.7.1 KEY TECHNOLOGIES
    • 5.7.1.1 Solid-phase synthesis
    • 5.7.1.2 Liquid-phase synthesis
    • 5.7.1.3 Enzymatic oligo synthesis
  • 5.7.2 COMPLEMENTARY TECHNOLOGIES
    • 5.7.2.1 Polymerase chain reaction (PCR)
    • 5.7.2.2 Next-generation sequencing
    • 5.7.2.3 Microarray analysis
  • 5.7.3 ADJACENT TECHNOLOGIES
    • 5.7.3.1 CRISPR
    • 5.7.3.2 Lipid nanoparticles
• 5.8 PRICING ANALYSIS
  • 5.8.1 AVERAGE SELLING PRICE TREND OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS, BY KEY PLAYERS, 2022-2024
  • 5.8.2 AVERAGE SELLING PRICE TREND OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS, 2022-2024
  • 5.8.3 AVERAGE SELLING PRICE TREND OF OLIGONUCLEOTIDE-BASED DRUGS, BY KEY PLAYERS, 2022-2024
  • 5.8.4 AVERAGE SELLING PRICE OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS, BY REGION, 2024
  • 5.8.5 AVERAGE PRICING TREND OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS, BY KEY PLAYERS, 2024
  • 5.8.6 AVERAGE PRICING TREND OF OLIGONUCLEOTIDE-BASED DRUGS, BY REGION, 2024
• 5.9 PATENT ANALYSIS
  • 5.9.1 PATENTS FILED, BY DOCUMENT TYPE, 2014-2024
• 5.10 PIPELINE ANALYSIS
• 5.11 TRADE ANALYSIS
  • 5.11.1 IMPORT DATA (HS CODE 293499)
  • 5.11.2 EXPORT DATA (HS CODE 293499)
• 5.12 KEY CONFERENCES & EVENTS, 2025-2026
• 5.13 TARIFF & REGULATORY LANDSCAPE
  • 5.13.1 TARIFF DATA (HS CODE 2934.99, 3822.00)
    • 5.13.1.1 Trade policy updates affecting oligonucleotide synthesis market, 2022-2025
    • 5.13.1.2 Impact of Tariffs on pricing & supply chain
  • 5.13.2 REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS
  • 5.13.3 REGULATORY FRAMEWORK
• 5.14 PORTER'S FIVE FORCES ANALYSIS
  • 5.14.1 DEGREE OF COMPETITION
  • 5.14.2 BARGAINING POWER OF SUPPLIERS
  • 5.14.3 BARGAINING POWER OF BUYERS
  • 5.14.4 THREAT OF SUBSTITUTES
  • 5.14.5 THREAT OF NEW ENTRANTS
• 5.15 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.15.2 BUYING CRITERIA FOR END USERS
• 5.16 CASE STUDY ANALYSIS
  • 5.16.1 CASE STUDY 1: THERMO FISHER SCIENTIFIC LEVERAGED ITS OLIGONUCLEOTIDE SYNTHESIS EXPERTISE TO DELIVER LARGE-SCALE DYE-LABELED OLIGONUCLEOTIDES TO ITS CLIENT
  • 5.16.2 CASE STUDY 2: BAKER LAB UTILIZING TWIST BIOSCIENCES OLIGO POOLS FOR EVALUATING PROTEIN FOLDING
  • 5.16.3 CASE STUDY 3: ENHANCED MOTOR FUNCTION WITH SPINRAZA TREATMENT IN ADOLESCENTS WITH LATE-ONSET SMA
• 5.17 INVESTMENT/FUNDING SCENARIO
• 5.18 IMPACT OF GENERATIVE AI ON OLIGONUCLEOTIDE SYNTHESIS MARKET
• 5.19 TRUMP TARIFF IMPACT OVERVIEW: OLIGONUCLEOTIDE SYNTHESIS MARKET
  • 5.19.1 KEY TARIFF RATES
  • 5.19.2 PRICE IMPACT ANALYSIS
  • 5.19.3 KEY IMPACT ON VARIOUS REGIONS
    • 5.19.3.1 US
    • 5.19.3.2 Europe
    • 5.19.3.3 APAC
    • 5.19.3.4 Rest of the World
  • 5.19.4 END-USE INDUSTRY IMPACT
    • 5.19.4.1 Hospitals
    • 5.19.4.2 Pharmaceutical & biotechnology companies
    • 5.19.4.3 Diagnostic laboratories
    • 5.19.4.4 CROs & CDMOs
    • 5.19.4.5 Academic & research institutes

6 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT

• 6.1 INTRODUCTION
• 6.2 OLIGONUCLEOTIDE-BASED DRUGS
  • 6.2.1 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE
    • 6.2.1.1 Antisense oligonucleotide-based drugs
      • 6.2.1.1.1 Growing use of antisense oligos in oligonucleotide-based drugs to boost growth
    • 6.2.1.2 siRNA oligonucleotide-based drugs
      • 6.2.1.2.1 Large pipeline of products to favor market growth
    • 6.2.1.3 Other oligonucleotide-based drugs
• 6.3 SYNTHESIZED OLIGONUCLEOTIDES
  • 6.3.1 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT
    • 6.3.1.1 Primers
      • 6.3.1.1.1 Increasing applications of oligo primers in DNA sequencing and molecular diagnostics to drive growth
    • 6.3.1.2 Probes
      • 6.3.1.2.1 Advancements in molecular diagnostic technologies such as FISH and qPCR to support market growth
    • 6.3.1.3 DNA oligonucleotides
      • 6.3.1.3.1 Diverse usage of DNA oligos to support market growth
    • 6.3.1.4 RNA oligonucleotides
      • 6.3.1.4.1 Growing diagnostic and therapeutic applications of RNA oligos to propel growth
    • 6.3.1.5 Other synthesized oligonucleotides
  • 6.3.2 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE
    • 6.3.2.1 Custom oligonucleotides
      • 6.3.2.1.1 Increasing demand for custom oligonucleotides for therapeutic research studies to drive growth
    • 6.3.2.2 Predesigned oligonucleotides
      • 6.3.2.2.1 Ability of predesigned oligos to save time required in design and optimization to boost adoption
• 6.4 REAGENTS & CONSUMABLES
  • 6.4.1 GROWING DEMAND FOR OLIGOS IN SEQUENCING, DRUG DESIGN, AND GENE SYNTHESIS TO DRIVE MARKET GROWTH FOR REAGENTS
• 6.5 EQUIPMENT
  • 6.5.1 TECHNOLOGICAL INNOVATIONS IN OLIGONUCLEOTIDE SYNTHESIZERS TO DRIVE GROWTH IN EQUIPMENT MARKET

7 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION

• 7.1 INTRODUCTION
• 7.2 THERAPEUTIC APPLICATIONS
  • 7.2.1 THERAPEUTIC APPLICATIONS MARKET, BY DISEASE TYPE
    • 7.2.1.1 Neurological disorders
      • 7.2.1.1.1 Growing research on oligonucleotide-based drugs for treatment of DMD and SMA to drive market
    • 7.2.1.2 Rare diseases
      • 7.2.1.2.1 High specificity & efficacy of oligo-based drugs against rare diseases to support growth
    • 7.2.1.3 Other diseases
• 7.3 RESEARCH APPLICATIONS
  • 7.3.1 PCR
    • 7.3.1.1 Increasing use of PCR in molecular biology research to drive market
  • 7.3.2 SEQUENCING
    • 7.3.2.1 Advancements in sequencing technologies & low cost of DNA sequencing to boost market
  • 7.3.3 OTHER RESEARCH APPLICATIONS
• 7.4 DIAGNOSTIC APPLICATIONS
  • 7.4.1 INCREASING DEMAND FOR RAPID & SPECIFIC METHODS FOR DISEASE DETECTION SUPPORT MARKET GROWTH

8 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER

• 8.1 INTRODUCTION
• 8.2 HOSPITALS
  • 8.2.1 INCREASING FDA APPROVALS FOR OLIGONUCLEOTIDE-BASED DRUGS FOR RARE DISEASES TO DRIVE MARKET
• 8.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 8.3.1 GROWING APPLICATIONS OF OLIGOS IN DRUG DISCOVERY & THERAPEUTICS TO PROPEL MARKET
• 8.4 DIAGNOSTIC LABORATORIES
  • 8.4.1 RISING SIGNIFICANCE OF OLIGOS IN MOLECULAR DIAGNOSTICS TO FUEL MARKET
• 8.5 CONTRACT RESEARCH ORGANIZATIONS (CROS) & CONTRACT MANUFACTURING ORGANIZATIONS (CMOS)
  • 8.5.1 WIDE RANGE OF CUSTOMIZED OLIGO SERVICES TO SUPPORT MARKET GROWTH
• 8.6 ACADEMIC RESEARCH INSTITUTES
  • 8.6.1 GROWING USE OF OLIGOS FOR GENOMIC RESEARCH APPLICATIONS TO PROPEL MARKET

9 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY REGION

• 9.1 INTRODUCTION
• 9.2 NORTH AMERICA
  • 9.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK
  • 9.2.2 US
    • 9.2.2.1 Government initiatives and strategic developments by leading players to drive market
  • 9.2.3 CANADA
    • 9.2.3.1 Strong research infrastructure and availability of funding to support market growth
• 9.3 EUROPE
  • 9.3.1 EUROPE: MACROECONOMIC OUTLOOK
  • 9.3.2 GERMANY
    • 9.3.2.1 Government & private funding investments towards health research to drive market
  • 9.3.3 UK
    • 9.3.3.1 Strategic collaborations & partnerships between key market players to fuel market
  • 9.3.4 FRANCE
    • 9.3.4.1 Favorable government initiatives for genomics research to boost demand
  • 9.3.5 ITALY
    • 9.3.5.1 Increasing R&D expenditure for pharma & biotech companies to support market growth
  • 9.3.6 SPAIN
    • 9.3.6.1 Favorable funding investments for biomedical research to drive market
  • 9.3.7 REST OF EUROPE
• 9.4 ASIA PACIFIC
  • 9.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK
  • 9.4.2 CHINA
    • 9.4.2.1 Expansion of leading pharmaceutical & biotechnology companies to drive market
  • 9.4.3 JAPAN
    • 9.4.3.1 Growing research initiatives & strategic developments to boost demand
  • 9.4.4 INDIA
    • 9.4.4.1 Development of bioclusters and improvements in healthcare infrastructure to propel market
  • 9.4.5 AUSTRALIA
    • 9.4.5.1 Increasing government initiatives and research funding to support market growth
  • 9.4.6 SOUTH KOREA
    • 9.4.6.1 Growing research activities and strategic expansions in oligonucleotide synthesis to aid market
  • 9.4.7 REST OF ASIA PACIFIC
• 9.5 LATIN AMERICA
  • 9.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK
  • 9.5.2 BRAZIL
    • 9.5.2.1 Availability of leading oligo-based therapies to support market growth
  • 9.5.3 MEXICO
    • 9.5.3.1 Growing adoption of NGS technology to drive market
  • 9.5.4 ARGENTINA
    • 9.5.4.1 Increasing research collaborations and government support to boost market
  • 9.5.5 REST OF LATIN AMERICA
• 9.6 MIDDLE EAST
  • 9.6.1 MIDDLE EAST: MACROECONOMIC OUTLOOK
  • 9.6.2 GCC COUNTRIES
    • 9.6.2.1 Saudi Arabia (KSA)
      • 9.6.2.1.1 Increasing focus on research & government support to propel market
    • 9.6.2.2 United Arab Emirates (UAE)
      • 9.6.2.2.1 Growing focus on life sciences research to fuel market
    • 9.6.2.3 Other GCC countries
  • 9.6.3 REST OF MIDDLE EAST
• 9.7 AFRICA
  • 9.7.1 IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH
  • 9.7.2 AFRICA: MACROECONOMIC OUTLOOK

10 COMPETITIVE LANDSCAPE

• 10.1 INTRODUCTION
• 10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
• 10.3 REVENUE ANALYSIS (RESEARCH & DIAGNOSTIC APPLICATIONS)
  • 10.3.1 REVENUE ANALYSIS (RESEARCH & DIAGNOSTIC APPLICATIONS), 2022-2024
  • 10.3.2 REVENUE ANALYSIS (THERAPEUTIC APPLICATIONS), 2022-2024
• 10.4 MARKET SHARE ANALYSIS
  • 10.4.1 MARKET SHARE ANALYSIS (RESEARCH & DIAGNOSTIC APPLICATIONS), 2024
  • 10.4.2 MARKET SHARE ANALYSIS (THERAPEUTIC APPLICATIONS),2024
• 10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS (RESEARCH & DIAGNOSTIC APPLICATIONS), 2024
  • 10.5.1 STARS
  • 10.5.2 EMERGING LEADERS
  • 10.5.3 PERVASIVE PLAYERS
  • 10.5.4 PARTICIPANTS
• 10.6 COMPANY EVALUATION MATRIX: KEY PLAYERS (THERAPEUTIC APPLICATIONS), 2024
  • 10.6.1 STARS
  • 10.6.2 EMERGING LEADERS
  • 10.6.3 PERVASIVE PLAYERS
  • 10.6.4 PARTICIPANTS
  • 10.6.5 COMPANY FOOTPRINT:
    • 10.6.5.1 Company footprint (Research & diagnostic applications)
    • 10.6.5.2 Region footprint (Research & diagnostic applications)
    • 10.6.5.3 Product footprint (Research & diagnostic applications)
    • 10.6.5.4 Application footprint (Research & diagnostic applications)
    • 10.6.5.5 Company footprint (Therapeutic applications)
    • 10.6.5.6 Region footprint (Therapeutic applications)
    • 10.6.5.7 Product footprint (Therapeutic applications)
    • 10.6.5.8 Application footprint (Therapeutic applications)
• 10.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 10.7.1 PROGRESSIVE COMPANIES
  • 10.7.2 RESPONSIVE COMPANIES
  • 10.7.3 DYNAMIC COMPANIES
  • 10.7.4 STARTING BLOCKS
  • 10.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
    • 10.7.5.1 Detailed list of key startups/SMEs
    • 10.7.5.2 Competitive benchmarking of startups/SMEs
• 10.8 COMPANY VALUATION & FINANCIAL METRICS
  • 10.8.1 FINANCIAL METRICS (RESEARCH & DIAGNOSTIC APPLICATIONS)
  • 10.8.2 COMPANY VALUATION (RESEARCH & DIAGNOSTIC APPLICATIONS)
  • 10.8.3 FINANCIAL METRICS (THERAPEUTIC APPLICATIONS)
  • 10.8.4 COMPANY VALUATION (THERAPEUTIC APPLICATIONS)
• 10.9 BRAND/PRODUCT COMPARATIVE ANALYSIS
  • 10.9.1 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY PRODUCT (RESEARCH & DIAGNOSTIC APPLICATIONS)
  • 10.9.2 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY PRODUCT (THERAPEUTIC APPLICATIONS)
• 10.10 COMPETITIVE SCENARIO
  • 10.10.1 PRODUCT APPROVALS

11 COMPANY PROFILES

• 11.1 KEY PLAYERS (RESEARCH & DIAGNOSTIC APPLICATIONS)
  • 11.1.1 DANAHER CORPORATION
    • 11.1.1.1 Business overview
    • 11.1.1.2 Products offered
    • 11.1.1.3 Recent developments
      • 11.1.1.3.1 Deals
      • 11.1.1.3.2 Expansions
      • 11.1.1.3.3 Other developments
    • 11.1.1.4 MnM view
      • 11.1.1.4.1 Key strengths
      • 11.1.1.4.2 Strategic choices
      • 11.1.1.4.3 Weaknesses & competitive threats
  • 11.1.2 THERMO FISHER SCIENTIFIC INC.
    • 11.1.2.1 Business overview
    • 11.1.2.2 Products offered
    • 11.1.2.3 Recent developments
      • 11.1.2.3.1 Deals
    • 11.1.2.4 MnM view
      • 11.1.2.4.1 Key strengths
      • 11.1.2.4.2 Strategic choices
      • 11.1.2.4.3 Weaknesses & competitive threats
  • 11.1.3 MERCK KGAA
    • 11.1.3.1 Business overview
    • 11.1.3.2 Products offered
    • 11.1.3.3 Recent developments
      • 11.1.3.3.1 Deals
      • 11.1.3.3.2 Expansions
    • 11.1.3.4 MnM view
      • 11.1.3.4.1 Key strengths
      • 11.1.3.4.2 Strategic choices
      • 11.1.3.4.3 Weaknesses & competitive threats
  • 11.1.4 LGC LIMITED
    • 11.1.4.1 Business overview
    • 11.1.4.2 Products offered
    • 11.1.4.3 Recent developments
      • 11.1.4.3.1 Deals
      • 11.1.4.3.2 Expansions
    • 11.1.4.4 MnM view
      • 11.1.4.4.1 Key strengths
      • 11.1.4.4.2 Strategic choices
      • 11.1.4.4.3 Weaknesses & competitive threats
  • 11.1.5 EUROFINS SCIENTIFIC
    • 11.1.5.1 Business overview
    • 11.1.5.2 Products offered
    • 11.1.5.3 Recent developments
      • 11.1.5.3.1 Deals
      • 11.1.5.3.2 Expansions
    • 11.1.5.4 MnM view
      • 11.1.5.4.1 Key strengths
      • 11.1.5.4.2 Strategic choices
      • 11.1.5.4.3 Weaknesses & competitive threats
  • 11.1.6 AGILENT TECHNOLOGIES, INC.
    • 11.1.6.1 Business overview
    • 11.1.6.2 Products offered
    • 11.1.6.3 Recent developments
      • 11.1.6.3.1 Deals
      • 11.1.6.3.2 Expansions
  • 11.1.7 KANEKA CORPORATION
    • 11.1.7.1 Business overview
    • 11.1.7.2 Products offered
    • 11.1.7.3 Recent developments
      • 11.1.7.3.1 Expansions
  • 11.1.8 MARAVAI LIFESCIENCES
    • 11.1.8.1 Business overview
    • 11.1.8.2 Products offered
    • 11.1.8.3 Recent developments
      • 11.1.8.3.1 Deals
      • 11.1.8.3.2 Expansions
  • 11.1.9 AZENTA US INC.
    • 11.1.9.1 Business overview
    • 11.1.9.2 Products offered
  • 11.1.10 TWIST BIOSCIENCE
    • 11.1.10.1 Business overview
    • 11.1.10.2 Products offered
    • 11.1.10.3 Recent developments
      • 11.1.10.3.1 Deals
  • 11.1.11 GENSCRIPT
    • 11.1.11.1 Business overview
    • 11.1.11.2 Products offered
    • 11.1.11.3 Recent developments
      • 11.1.11.3.1 Deals
      • 11.1.11.3.2 Expansions
• 11.2 KEY PLAYERS (THERAPEUTIC APPLICATIONS)
  • 11.2.1 BIOGEN
    • 11.2.1.1 Business overview
    • 11.2.1.2 Products offered
    • 11.2.1.3 Recent developments
      • 11.2.1.3.1 Product approvals
      • 11.2.1.3.2 Deals
      • 11.2.1.3.3 Expansions
    • 11.2.1.4 MnM view
      • 11.2.1.4.1 Key strengths
      • 11.2.1.4.2 Strategic choices
      • 11.2.1.4.3 Weaknesses & competitive threats
  • 11.2.2 ALNYLAM PHARMACEUTICALS, INC.
    • 11.2.2.1 Business overview
    • 11.2.2.2 Products offered
    • 11.2.2.3 Recent developments
      • 11.2.2.3.1 Product approvals
      • 11.2.2.3.2 Deals
    • 11.2.2.4 MnM view
      • 11.2.2.4.1 Key strengths
      • 11.2.2.4.2 Strategic choices
      • 11.2.2.4.3 Weaknesses & competitive threats
  • 11.2.3 SAREPTA THERAPEUTICS, INC.
    • 11.2.3.1 Business overview
    • 11.2.3.2 Products offered
    • 11.2.3.3 Recent developments
      • 11.2.3.3.1 Product approvals
      • 11.2.3.3.2 Expansions
    • 11.2.3.4 MnM view
      • 11.2.3.4.1 Key strengths
      • 11.2.3.4.2 Strategic choices
      • 11.2.3.4.3 Weaknesses & competitive threats
  • 11.2.4 ASTRAZENECA
    • 11.2.4.1 Business overview
    • 11.2.4.2 Products offered
    • 11.2.4.3 Recent developments
      • 11.2.4.3.1 Deals
      • 11.2.4.3.2 Product Approvals
    • 11.2.4.4 MnM view
      • 11.2.4.4.1 Key strengths
      • 11.2.4.4.2 Strategic choices
      • 11.2.4.4.3 Weaknesses & competitive threats
  • 11.2.5 ASTELLAS PHARMA INC.
    • 11.2.5.1 Business overview
    • 11.2.5.2 Products offered
    • 11.2.5.3 Recent developments
      • 11.2.5.3.1 Deals
      • 11.2.5.3.2 Product approvals
    • 11.2.5.4 MnM view
      • 11.2.5.4.1 Key strengths
      • 11.2.5.4.2 Strategic choices
      • 11.2.5.4.3 Weaknesses & competitive threats
  • 11.2.6 JAZZ PHARMACEUTICALS PLC
    • 11.2.6.1 Business overview
    • 11.2.6.2 Products offered
  • 11.2.7 NIPPON SHINYAKU, CO. LTD.
    • 11.2.7.1 Business overview
    • 11.2.7.2 Products offered
    • 11.2.7.3 Recent developments
      • 11.2.7.3.1 Deals
  • 11.2.8 IONIS PHARMACEUTICALS, INC.
    • 11.2.8.1 Business overview
    • 11.2.8.2 Products offered
    • 11.2.8.3 Recent developments
      • 11.2.8.3.1 Product Approvals
      • 11.2.8.3.2 Deals
  • 11.2.9 NOVARTIS AG
    • 11.2.9.1 Business overview
    • 11.2.9.2 Products offered
    • 11.2.9.3 Recent developments
      • 11.2.9.3.1 Product Approvals
      • 11.2.9.3.2 Deals
• 11.3 OTHER PLAYERS
  • 11.3.1 OLIGOMAKER APS (PART OF TAG COPENHAGEN A/S)
  • 11.3.2 BIOLEGIO B.V.
  • 11.3.3 BIOLYTIC LAB PERFORMANCE, INC.
  • 11.3.4 BIOCOMMA LIMITED
  • 11.3.5 REVVITY (SUBSIDIARY OF HORIZON DISCOVERY LTD.)
  • 11.3.6 BIO-SYNTHESIS, INC.
  • 11.3.7 CREATIVE BIOGENE
  • 11.3.8 REPROCELL INC. (THROUGH SUBSIDIARY BIOSERVE)

12 APPENDIX

• 12.1 DISCUSSION GUIDE
• 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 12.3 CUSTOMIZATION OPTIONS
• 12.4 RELATED REPORTS
• 12.5 AUTHOR DETAILS